Follow-up and percentage of time spent within, below, and above the INR range depending on INR target in warfarin-treated patients
| . | Follow-up, d, mean ± SD (min-max) . | Time spent within the INR range, %, mean ± SD (min-max) . | Time spent below the INR range, %, mean ± SD (min-max) . | Time spent above the INR range, %, mean ± SD (min-max) . |
|---|---|---|---|---|
| INR range 1.5-3.3 (target 2.2; n = 18) | 285 ± 203 (29-571) | 93.0 ± 9.5 (75.4-1) | 4.2 ± 9.5 (0-34.5) | 2.8 ± 3.9 (0-12.5) |
| INR range 1.8-3.2 (target 2.5; n = 14) | 323 ± 220 (32-768) | 83.5 ± 11.6 (56.4-1) | 8.0 ± 8.1 (0-24.1) | 8.5 ± 9.1 (0-28.7) |
| INR range 2.5-4 (target 3.3; n = 29) | 511 ± 207 (80-776) | 69.8 ± 13.6 (45.9-97.7) | 9.3 ± 9.2 (0-35.9) | 21.0 ± 10.1 (23.3-34.3) |
| Total (n = 61) | 354 ± 226 | 83.3 ± 14.6 | 7.1 ± 8.9 | 9.6 ± 10.5 |
| . | Follow-up, d, mean ± SD (min-max) . | Time spent within the INR range, %, mean ± SD (min-max) . | Time spent below the INR range, %, mean ± SD (min-max) . | Time spent above the INR range, %, mean ± SD (min-max) . |
|---|---|---|---|---|
| INR range 1.5-3.3 (target 2.2; n = 18) | 285 ± 203 (29-571) | 93.0 ± 9.5 (75.4-1) | 4.2 ± 9.5 (0-34.5) | 2.8 ± 3.9 (0-12.5) |
| INR range 1.8-3.2 (target 2.5; n = 14) | 323 ± 220 (32-768) | 83.5 ± 11.6 (56.4-1) | 8.0 ± 8.1 (0-24.1) | 8.5 ± 9.1 (0-28.7) |
| INR range 2.5-4 (target 3.3; n = 29) | 511 ± 207 (80-776) | 69.8 ± 13.6 (45.9-97.7) | 9.3 ± 9.2 (0-35.9) | 21.0 ± 10.1 (23.3-34.3) |
| Total (n = 61) | 354 ± 226 | 83.3 ± 14.6 | 7.1 ± 8.9 | 9.6 ± 10.5 |
Target INR was 2.2 in patients with total cavopulmonary connection; of 2.5 in those with aortic valve replacement, dilated cardiomyopathy, coronary aneurysms after Kawasaki disease, or extracardiac diseases; and 3.3 in those with mitral valve replacement.